| 4/16/2021 |
Merck's Covid-19 drug R&D falls short twice in treating hospitalized patients |
MedCity News |
Pharma , BioPharma Merck’s Covid-19 drug R&D falls short twice in treating hospitalized patients Merck is discontinuing work on one Covid-19 drug for treating hospitalized patients after the FDA said it needs more clinical data . Another Merck drug candidate is moving forward only in outpatient testing after independent clinical trial observers concluded the antiviral was unlikely to help those in the hospital ... |
| 4/16/2021 |
What are the health benefits of moringa? - South Florida Sun-Sentinel |
Chicago Tribune |
... moringa tree — commonly consumed in powdered form — also boast highly digestible plant protein that is readily absorbed by your system, rivaling the nutritional profile of foods like eggs, dairy or kale. While clinical data is still limited, moringa has been shown to support healthy lactation and be protective against chronic disease.Known as the “drumstick tree” for its long seed pods, and “miracle tree” and “horseradish tree ... |
| 4/16/2021 |
Cara Therapeutics Inc. (NASDAQ:CARA) and Vifor Pharma Announce EMA Review Of Its Difelikefalin MAA |
mmjreporter.com |
... review the MAA application as per the centralized marketing authorization procedure. EMA to give MAA decision for difelikefalin use in the US in Q2 2022The companies will support the EMA filing with positive clinical data from pivotal Phase II trials KALM-1 and KALM-2 and additional supportive data from 32 clinical studies. Once approved, difelikefalin will receive marketing authorization in all EU member states and Liechtenstein, Norway, and ... |
| 4/16/2021 |
TRIO Partners with eClinical Solutions to Power Digital Transformation in Clinical Trials for Cancer |
mysanantonio.com |
TRIO Partners with eClinical Solutions to Power Digital Transformation in Clinical Trials for Cancer PRWebGlobal clinical research organization selects eClinical’s elluminate clinical data platform to optimize trial efficiency and speed MANSFIELD, Mass.eClinical Solutions LLC , a global provider of cloud-based enterprise software and software-driven clinical data services that accelerate digital clinical initiatives, today announced that Translational Research in Oncology (TRIO) , a global academic clinical research organization ... |
| 4/15/2021 |
Exscientia Announces First AI-Designed Immuno-Oncology Drug to Enter Clinical Trials |
drugdiscoverytoday.com |
Exscientia Announces First AI-Designed Immuno-Oncology Drug to Enter Clinical Trials15 April 2021 Company’s technologies and drug-hunting expertise now responsible for world’s first and second AI-designed drugs to enter Phase I testing Exscientia, a leading artificial intelligence (AI)-driven pharmatech company, today announced the first AI-designed molecule for immuno-oncology to enter human clinical trials. The A2a receptor antagonist, which is in development ... |
| 4/15/2021 |
Impact of idiopathic pulmonary fibrosis on clinical outcomes of lung cancer patients |
Nature |
Abstract The clinical characteristics of lung cancer in patients with idiopathic pulmonary fibrosis (IPF) differ from those of lung cancer in patients without IPF. Thus, we aimed to evaluate the impact of IPF on the clinical course of patients with lung cancer. Clinical data of IPF patients with lung cancer (n = 122) were compared with those of patients with lung cancer without IPF (n = 488) matched by age, sex, histopathology ... |
| 4/15/2021 |
GSK Halts Two Mid-Stage Studies of ICOS Agonist |
pharmalive.com |
... it halted the two studies with feladilimab, an investigational inducible T cell co-stimulatory (ICOS) agonist. It is likely the IDMC discovered the drug was not delivering the desired safety and efficacy from available clinical data .This isn’t the first time an ICOS agonist has run into clinical trouble. In November 2020, Jounce Therapeutics announced its asset vopratelimab would not meet endpoints in its study following an interim analysis ... |
| 4/15/2021 |
TRIO Partners with eClinical Solutions to Power Digital Transformation in Clinical Trials for Cancer |
clinicalresearchnewsonline.com |
TRIO Partners with eClinical Solutions to Power Digital Transformation in Clinical Trials for Cancer Mansfield, MA, April 15, 2021 — eClinical Solutions LLC, a global provider of cloud-based enterprise software and software-driven clinical data services that accelerate digital clinical initiatives, today announced that Translational Research in Oncology (TRIO), a global academic clinical research organization (CRO), has selected eClinical’s elluminate® clinical data platform to modernize trial processes ... |
| 4/15/2021 |
TRIO Partners with eClinical Solutions to Power Digital Transformation in Clinical Trials for Cancer |
pharmavoice.com |
Global clinical research organization selects eClinical’s elluminate clinical data platform to optimize trial efficiency and speedMansfield, MA, April 15, 2021 — eClinical Solutions LLC , a global provider of cloud-based enterprise software and software-driven clinical data services that accelerate digital clinical initiatives, today announced that Translational Research in Oncology (TRIO) , a global academic clinical research organization (CRO), has selected eClinical’s elluminate® clinical data platform to ... |
| 4/15/2021 |
eClinical Solutions Shares Business Strategies for Accelerated Clinical Trials Post Covid-19 |
clinicalresearchnewsonline.com |
eClinical Solutions Shares Business Strategies for Accelerated Clinical Trials Post Covid-19 Mansfield, MA, April 13, 2021 — eClinical Solutions LLC, a global provider of cloud-based enterprise software and software-driven clinical data services that accelerate digital clinical initiatives, today announced that senior thought leaders from eClinical will speak at several key upcoming industry events. Their topics include increasing the speed of clinical development, navigating decentralized trial models, and ... |
| 4/14/2021 |
PsiOxus and bluebird bio Present Novel Data Combining PsiOxus T-SIGn Platform with CAR-T Therapy to Clear Primary Tumors and Metastases |
financialbuzz.com |
PsiOxus Therapeutics, Ltd . (PsiOxus), a clinical stage oncology company ​re-programming ​the tumor microenvironment to overcome the central challenge of resistance to therapy, and bluebird bio, Inc. (Nasdaq: BLUE) presented preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2021. The study, “T-SIGn cancer gene therapy and anti-EGFR CAR-T cells synergize in combination therapy to clear A549 lung tumor xenografts”, assessed anti-tumor ... |
| 4/14/2021 |
On a roll, Gilead snags 2nd Trodelvy nod—in bladder cancer—but Seagen and Astellas have set the bar high |
FiercePharma |
... wasn’t a major driver in Gilead’s decision to spend $21 billion on Trodelvy’s developer, Immunomedics. But the drug could have had more opportunity if it weren’t for the even better clinical data that Seagen and partner Astellas recently posted for their own antibody-drug conjugate, Padcev.Trodelvy earned its bladder cancer go-ahead with early results from the phase 2 Trophy-U-01 study. Of the ... |
| 4/14/2021 |
Federal Advisory Panel to Meet Wednesday on J&J Vaccine - WSJ |
The Wall Street Journal |
... health officials on Tuesday recommended that use of the J&J vaccine be paused while they investigate.The ACIP, which advises the Centers for Disease Control and Prevention on vaccination policy, met to review clinical data gathered to date on six women between the ages of 18 and 48 years old who developed clots in vessels draining blood from their brains and in some cases other parts of the body ... |
| 4/14/2021 |
COVID-19 Infection May Up Mortality in Surgical Patients |
Physicians Weekly |
... 7.1 percent) — a pattern seen for public hospitals and nonprofit hospitals, but not for private hospitals. There were no significant differences noted between the groups for rates of complications listed in the Vizient Clinical Data Base nor median length of stay. However, among patients with COVID-19, hospital-acquired conditions and patient safety indicators were higher. The investigators observed no differences in mortality rates, complications, hospital-acquired conditions, or ... |
| 4/13/2021 |
Merck posts early clinical data on subcutaneous Keytruda, setting stage for further studies |
FiercePharma |
Apr 13, 2021 7:40am Merck researchers outlined plans to assess subcutaneous formulations in other tumor types. (Merck & Co.)Merck has presented early clinical data on subcutaneous formulations of its blockbuster checkpoint inhibitor Keytruda. The data drop is an early step in an ongoing effort to reformulate Keytruda ahead of the anticipated expiration of U.S. patents in 2028.Keytruda and rival checkpoint inhibitors are currently given intravenously. However, as in other ... |
| 4/13/2021 |
Prevalence of Syphilis among Pregnant Women Attending Antenatal Care Clinic |
Physicians Weekly |
... included a total of 210 participants. The entire participants were recruited by systematic random sampling method after proportional allocation of the sample size in the two health centers. A semistructured questioner collected sociodemographic and clinical data . The association between independent and dependent variables was determined using chi-square. A P-value less than 0.05 was considered statistically significant. Women with multiple sexual partners and the late trimester of pregnancy during ... |
| 4/13/2021 |
Conference data for April 13, 2021: AACR 04-13 |
BioWorld |
New and updated preclinical and clinical data presented by biopharma firms at the American Association for Cancer Research Annual Meeting, including: Gracell, Hummingbird ... |
| 4/13/2021 |
Conference data for April 13, 2021: AACR 13 |
BioWorld |
New and updated preclinical and clinical data presented by biopharma firms at the American Association for Cancer Research Annual Meeting 2021, including: BMS, Kronos, Kymera, Medicenna, Medigene, Mei, Mersana, Mirati, Molecular Partners, Molecular Templates, Morphic, Nextcure, Nuvalent, Oasmia, Oncolytics, Oncomyx, Oncurious, Oncternal, Oric, Pharmabcine, Phio, Pieris, PMV, Puretech, Schrodinger, Seneca ... |
| 4/13/2021 |
Quartesian Signs Global Medical Technology Company to Multi-Year Clinical Data Management Services Agreement |
PR Newswire |
... technology company. Under the agreement Quartesian is providing Electronic Data Capture (EDC) programming using Medidata Rave EDC, full data management, and SAS statistical services in support of several franchises.Quartesian specializes in high quality clinical data at affordable rates. To update the client's processes and systems with modern EDC technology, they required a partner who had both expertise and broad experience with Medidata's electronic data capture platform. Quartesian collaborated with ... |
| 4/13/2021 |
eClinical Solutions Shares Business Strategies for Accelerated Clinical Trials Post Covid-19 |
pharmavoice.com |
eClinical thought leaders to discuss decentralized trials, digital transformation of clinical research and modernized clinical data infrastructures at upcoming industry eventsMansfield, MA, April 13, 2021 — eClinical Solutions LLC , a global provider of cloud-based enterprise software and software-driven clinical data services that accelerate digital clinical initiatives, today announced that senior thought leaders from eClinical will speak at several key upcoming industry events. Their topics include increasing the ... |